Clinical biomarkers in adjuvant chemotherapy for gastric cancer after D2 dissection by a pooled analysis of individual patient data from large randomized controlled trials

[1] Bray F(2018)Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries CA Cancer J Clin 68 394-424

[2] Ferlay J(2001)Chemoradiotherapy after surgery compared with surgery alone for adenocarcinoma of the stomach or gastroesophageal junction N Engl J Med 345 725-730

[3] Soerjomataram I(2006)Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer N Engl J Med 355 11-20

[4] Macdonald JS(2007)Adjuvant chemotherapy for gastric cancer with S-1, an oral fluoropyrimidine N Engl J Med 357 1810-1820

[5] Smalley SR(2006)Adjuvant chemotherapy using S-1 for curatively resected gastric cancer-the nationwide clinical trial Gan To Kagaku Ryoho 33 110-116

[6] Benedetti J(2012)Adjuvant capecitabine and oxaliplatin for gastric cancer after D2 gastrectomy (CLASSIC): a phase 3 open-label, randomised controlled trial Lancet 379 315-321

[7] Cunningham D(2014)Sequential paclitaxel followed by tegafur and uracil (UFT) or S-1 versus UFT or S-1 monotherapy as adjuvant chemotherapy for T4a/b gastric cancer (SAMIT): a phase 3 factorial randomised controlled trial Lancet Oncol 15 886-893

[8] Allum WH(2018)Comparative effectiveness of adjuvant treatments for resected gastric cancer: a network meta-analysis Gastric Cancer 21 1031-1040

[9] Stenning SP(2018)Identification of clinical biomarkers for adjuvant chemotherapy for gastric cancer after D2 dissection by pooled analysis of individual patent data from large randomized clinical trials Ann Cancer Res Ther. 26 43-45

[10] Sakuramoto S(2015)Preferred reporting items for systematic review and meta-analyses of individual participant data: the PRISMA-IPD statement JAMA 313 1657-1665

[1] Bray F(2018)Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries CA Cancer J Clin 68 394-424

[2] Ferlay J(2001)Chemoradiotherapy after surgery compared with surgery alone for adenocarcinoma of the stomach or gastroesophageal junction N Engl J Med 345 725-730

[3] Soerjomataram I(2006)Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer N Engl J Med 355 11-20

[4] Macdonald JS(2007)Adjuvant chemotherapy for gastric cancer with S-1, an oral fluoropyrimidine N Engl J Med 357 1810-1820

[5] Smalley SR(2006)Adjuvant chemotherapy using S-1 for curatively resected gastric cancer-the nationwide clinical trial Gan To Kagaku Ryoho 33 110-116

[6] Benedetti J(2012)Adjuvant capecitabine and oxaliplatin for gastric cancer after D2 gastrectomy (CLASSIC): a phase 3 open-label, randomised controlled trial Lancet 379 315-321

[7] Cunningham D(2014)Sequential paclitaxel followed by tegafur and uracil (UFT) or S-1 versus UFT or S-1 monotherapy as adjuvant chemotherapy for T4a/b gastric cancer (SAMIT): a phase 3 factorial randomised controlled trial Lancet Oncol 15 886-893

[8] Allum WH(2018)Comparative effectiveness of adjuvant treatments for resected gastric cancer: a network meta-analysis Gastric Cancer 21 1031-1040

[9] Stenning SP(2018)Identification of clinical biomarkers for adjuvant chemotherapy for gastric cancer after D2 dissection by pooled analysis of individual patent data from large randomized clinical trials Ann Cancer Res Ther. 26 43-45

[10] Sakuramoto S(2015)Preferred reporting items for systematic review and meta-analyses of individual participant data: the PRISMA-IPD statement JAMA 313 1657-1665